A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia.

Trial Profile

A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Feb 2018

At a glance

  • Drugs Palifermin (Primary) ; Pegaspargase (Primary) ; Nelarabine; Rituximab
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms UKALL-14
  • Most Recent Events

    • 12 Feb 2018 Planned End Date changed from 30 Dec 2016 to 31 Dec 2023.
    • 22 Oct 2017 Planned number of patients changed from 720 to 811.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top